FY2023 Earnings Forecast for Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Issued By Brookline Capital Management

Syros Pharmaceuticals, Inc. (NASDAQ:SYRSFree Report) – Equities research analysts at Brookline Capital Management reduced their FY2023 EPS estimates for shares of Syros Pharmaceuticals in a research note issued to investors on Tuesday, November 14th. Brookline Capital Management analyst L. Cann now expects that the company will post earnings of ($4.96) per share for the year, down from their previous estimate of ($4.64). The consensus estimate for Syros Pharmaceuticals’ current full-year earnings is ($4.41) per share. Brookline Capital Management also issued estimates for Syros Pharmaceuticals’ Q4 2023 earnings at ($1.46) EPS, FY2024 earnings at ($4.42) EPS, FY2025 earnings at ($2.35) EPS, FY2026 earnings at $4.52 EPS and FY2027 earnings at $18.12 EPS.

A number of other brokerages also recently commented on SYRS. StockNews.com initiated coverage on Syros Pharmaceuticals in a research report on Thursday, October 5th. They issued a “hold” rating for the company. HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Syros Pharmaceuticals in a research note on Wednesday, August 9th. Finally, Piper Sandler lowered their target price on shares of Syros Pharmaceuticals from $11.00 to $7.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 3rd. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $12.50.

Check Out Our Latest Report on Syros Pharmaceuticals

Syros Pharmaceuticals Stock Down 0.7 %

SYRS stock opened at $2.98 on Friday. Syros Pharmaceuticals has a twelve month low of $2.09 and a twelve month high of $5.67. The company has a quick ratio of 5.38, a current ratio of 4.31 and a debt-to-equity ratio of 1.09. The company has a market cap of $62.78 million, a PE ratio of -0.79 and a beta of 1.46. The business’s 50-day simple moving average is $3.05 and its 200 day simple moving average is $3.38.

Institutional Trading of Syros Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Private Advisor Group LLC bought a new position in shares of Syros Pharmaceuticals in the first quarter valued at approximately $29,000. Sawtooth Solutions LLC acquired a new stake in Syros Pharmaceuticals during the 1st quarter valued at $29,000. Prudential Financial Inc. bought a new position in Syros Pharmaceuticals in the 2nd quarter valued at $32,000. BNP Paribas Arbitrage SA boosted its stake in Syros Pharmaceuticals by 540.4% in the second quarter. BNP Paribas Arbitrage SA now owns 34,608 shares of the company’s stock worth $33,000 after purchasing an additional 29,204 shares in the last quarter. Finally, Walleye Trading LLC bought a new stake in shares of Syros Pharmaceuticals during the first quarter worth $36,000. 51.29% of the stock is owned by institutional investors.

Syros Pharmaceuticals Company Profile

(Get Free Report)

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.

Further Reading

Earnings History and Estimates for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.